The Novo Nordisk Foundation has proposed new candidates for election as members of the Board of Directors of Novo Nordisk A/S, putting fresh leadership choices before shareholders of one of Europe's most valuable pharmaceutical companies.

The Foundation, the controlling shareholder of Novo Nordisk A/S, has put forward the names as part of the formal election process for the company's board. The proposal signals how the owner intends to shape the governance of the group at a moment when board composition carries unusual weight with investors.

What has the Foundation actually proposed?

The proposal concerns candidates for election as board members of Novo Nordisk A/S, the Danish pharmaceutical manufacturer. As the company's majority owner, the Novo Nordisk Foundation exercises its shareholder rights by nominating candidates ahead of the shareholder vote.

The Foundation announced the proposal through its official channel, Novo Nordisk Fonden. No further details on individual candidate backgrounds were contained in the announcement as distributed.

For shareholders, the practical significance is straightforward:

• The Foundation, as controlling owner, selects the slate of candidates for the board.
• Shareholders of Novo Nordisk A/S vote on the candidates at the relevant election.
• Board composition determines oversight of executive leadership, strategy and capital allocation at the company.

Why does this nomination matter?

Novo Nordisk A/S is one of the largest companies on the Copenhagen stock market, and its governance moves are watched closely by institutional investors across Europe. The Foundation's role as majority owner means its candidate list effectively determines who joins the board.

Board elections at Novo Nordisk follow the standard Danish corporate governance framework. The nomination committee process, the owner's proposal and the shareholder vote together decide the final composition of the board of directors.

The timing of the proposal aligns with the corporate election cycle, in which nominations are published ahead of the shareholders' meeting where the vote takes place. Candidates proposed by the Foundation historically form the core of the elected board, given the owner's voting power.

What happens next?

Shareholders will consider the proposed candidates at the upcoming election. If approved, the new members join the existing directors in overseeing the company's executive board, chaired leadership structure and strategic direction.

Investors and analysts tracking Novo Nordisk will look at the final board composition for signals about continuity or change in the company's governance priorities. The Foundation's proposal is the decisive step in that process, given its controlling stake.

CEO Frontier will monitor the outcome of the election and any subsequent changes to the board's committee assignments.